In this study, we have demonstrated that ~20% of the ovarian tumors can be identified with a pathogenic SNV/indel in BRCA1/2 while another ~10% will have a pathogenic CNV or a promoter DNA methylation defect in these genes. Here, BRCA1 is linked to ovarian neoplasm.